Download PDF
Semin Neurol 2022; 42(05): 558-570
DOI: 10.1055/s-0042-1758781
Review Article

Prevention of Migraine

Ashley Holdridge 
1   Department of Neurology and Headache, Advocate Aurora HealthCare, Whitefish Bay, Wisconsin
,
Jennifer Buczyner
2   Department of Neurology, First Choice Neurology, Palm Beach Gardens, Florida
,
Cristina Cabret Aymat
3   Department of Neurology and Headache, Ochsner Health Center – Covington, Covington, Louisiana
,
Ariel Le
2   Department of Neurology, First Choice Neurology, Palm Beach Gardens, Florida
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Migraine, a primary headache disorder is a chronic and complex neurological disease that affects millions of people worldwide, impacting their quality of life. It is one of the most common reasons why individuals seek the advice of their physician, and is one of the most common referrals seen in the offices of general neurologists and headache specialists. In the past decade, there has been robust research on not only the pathophysiology of migraine but in the efforts to treat and, importantly, prevent. The introduction of calcitonin gene related peptide antagonists (CGRP-A) have opened new doors for preventive treatment options. OnabotulinumtoxinA (BoNTA) has remained a staple in the treatment of chronic migraine with data emerging with combination therapy. Neurostimulation has offered additional nonpharmacologic approaches to migraine treatment. In addition to lifestyle and behavioral modifications, these have changed the landscape of migraine prevention.

Keywords

migraine - headache - prevention - treatment - prophylaxis - CGRP


Publication History

Article published online:
13 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38 (01) 1-211
    Google Scholar
  • 2 Buse DC, Scher AI, Dodick DW. et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO Study. Mayo Clin Proc 2016; 91 (05) 596-611
    CrossrefPubMedGoogle Scholar
  • 3 Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache 2021; 61 (01) 60-68
    CrossrefPubMedGoogle Scholar
  • 4 Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache 2018; 58 (05) 700-714
    CrossrefPubMedGoogle Scholar
  • 5 Recober A. Pathophysiology of migraine. Continuum (Minneap Minn) 2021; 27 (03) 586-596
    PubMedGoogle Scholar
  • 6 Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol 2018; 14 (12) 699-710
    CrossrefPubMedGoogle Scholar
  • 7 Viana M, Sances G, Ghiotto N. et al. Variability of the characteristics of a migraine attack within patients. Cephalalgia 2016; 36 (09) 825-830
    CrossrefPubMedGoogle Scholar
  • 8 Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician 2019; 99 (01) 17-24
    PubMedGoogle Scholar
  • 9 Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68 (05) 343-349
    CrossrefPubMedGoogle Scholar
  • 10 Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22 (07) 491-512
    CrossrefPubMedGoogle Scholar
  • 11 Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015; 35 (06) 478-488
    CrossrefPubMedGoogle Scholar
  • 12 Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn) 2015; 21 (4 Headache) 973-989
    CrossrefPubMedGoogle Scholar
  • 13 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. [published correction appears in Neurology. 2013 Feb 26;80(9):871] Neurology 2012; 78 (17) 1337-1345
    CrossrefPubMedGoogle Scholar
  • 14 Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48 (08) 1157-1168
    CrossrefPubMedGoogle Scholar
  • 15 Burch R. Preventive migraine treatment. [published correction appears in Continuum (Minneap Minn) 2021 Oct 1;27(5):1494–1495] Continuum (Minneap Minn) 2021; 27 (03) 613-632
    PubMedGoogle Scholar
  • 16 Lipton RB, Bigal ME, Amatniek JC, Stewart WF. Tools for diagnosing migraine and measuring its severity. Headache 2004; 44 (05) 387-398
    CrossrefPubMedGoogle Scholar
  • 17 Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000; 88 (01) 41-52
    CrossrefPubMedGoogle Scholar
  • 18 Jacobson GP, Ramadan NM, Aggarwal SK, Newman CW. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology 1994; 44 (05) 837-842
    CrossrefPubMedGoogle Scholar
  • 19 Houts CR, Wirth RJ, McGinley JS. et al. Content validity of HIT-6 as a measure of headache impact in people with migraine: a narrative review. Headache 2020; 60 (01) 28-39
    CrossrefPubMedGoogle Scholar
  • 20 Adams AM, Serrano D, Buse DC. et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 2015; 35 (07) 563-578
    CrossrefPubMedGoogle Scholar
  • 21 Woolley JM, Bonafede MM, Maiese BA, Lenz RA. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache 2017; 57 (09) 1399-1408
    CrossrefPubMedGoogle Scholar
  • 22 Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014; 20 (01) 22-33
    CrossrefPubMedGoogle Scholar
  • 23 Blumenfeld AM, Bloudek LM, Becker WJ. et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 2013; 53 (04) 644-655
    CrossrefPubMedGoogle Scholar
  • 24 Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol 2007; 7 (06) 383-393
    CrossrefPubMedGoogle Scholar
  • 25 Freitag FG, Collins SD, Carlson HA. et al; Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58 (11) 1652-1659
    CrossrefPubMedGoogle Scholar
  • 26 Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17 (02) 103-108
    CrossrefPubMedGoogle Scholar
  • 27 Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; (06) CD010610
    PubMedGoogle Scholar
  • 28 Starling AJ, Vargas BB. A narrative review of evidence-based preventive options for chronic migraine. Curr Pain Headache Rep 2015; 19 (10) 49
    CrossrefPubMedGoogle Scholar
  • 29 Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache 2017; 57 (01) 165-178
    CrossrefPubMedGoogle Scholar
  • 30 do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of β-blockers: history, class differences and clinical applicability. Curr Hypertens Rev 2019; 15 (01) 22-31
    CrossrefPubMedGoogle Scholar
  • 31 Jackson JL, Kuriyama A, Kuwatsuka Y. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019; 14 (03) e0212785
    CrossrefPubMedGoogle Scholar
  • 32 Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322 (7277): 19-22
    CrossrefPubMedGoogle Scholar
  • 33 Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289 (01) 65-69
    CrossrefPubMedGoogle Scholar
  • 34 Baskin SM, Smitherman TA. Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications. Neurol Sci 2009; 30 (Suppl. 01) S61-S65
    CrossrefPubMedGoogle Scholar
  • 35 Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore) 2017; 96 (22) e6989
    CrossrefPubMedGoogle Scholar
  • 36 Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol 2019; 21 (04) 18
    CrossrefPubMedGoogle Scholar
  • 37 Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (02) 144-152
    CrossrefPubMedGoogle Scholar
  • 38 Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom 2018; 87 (04) 195-203
    CrossrefPubMedGoogle Scholar
  • 39 Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry 2008; 69 (09) 1449-1454
    CrossrefPubMedGoogle Scholar
  • 40 Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018; 75 (05) 566-572
    CrossrefPubMedGoogle Scholar
  • 41 Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J 2013; 13 (04) 533-540
    PubMedGoogle Scholar
  • 42 Pavlović JM, Stewart WF, Bruce CA. et al. Burden of migraine related to menses: results from the AMPP study. J Headache Pain 2015; 16 (01) 24
    CrossrefPubMedGoogle Scholar
  • 43 Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63 (02) 261-269
    CrossrefPubMedGoogle Scholar
  • 44 Silberstein S, Patel S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother 2014; 15 (14) 2063-2070
    CrossrefPubMedGoogle Scholar
  • 45 Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review. Headache 2020; 60 (07) 1259-1272
    CrossrefPubMedGoogle Scholar
  • 46 Dodick DW, Turkel CC, DeGryse RE. et al; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50 (06) 921-936
    CrossrefPubMedGoogle Scholar
  • 47 Aurora SK, Dodick DW, Turkel CC. et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30 (07) 793-803
    CrossrefPubMedGoogle Scholar
  • 48 Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache 2017; 57 (05) 766-777
    CrossrefPubMedGoogle Scholar
  • 49 Blumenfeld AM. Botox for Chronic Migraine: Tips and Tricks. Practical Neurology. February 2018. Accessed January 2, 2022 at: https://practicalneurology.com/articles/2018-feb/botox-for-chronic-migraine-tips-and-tricks
    PubMedGoogle Scholar
  • 50 Hargreaves R, Olesen J. Calcitonin gene-related peptide modulators - the history and renaissance of a new migraine drug class. Headache 2019; 59 (06) 951-970
    CrossrefPubMedGoogle Scholar
  • 51 Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets 2020; 24 (02) 91-100
    CrossrefPubMedGoogle Scholar
  • 52 Zobdeh F, Ben Kraiem A, Attwood MM. et al. Pharmacological treatment of migraine: drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol 2021; 178 (23) 4588-4607
    CrossrefPubMedGoogle Scholar
  • 53 Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28 (02) 183-187
    CrossrefPubMedGoogle Scholar
  • 54 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33 (01) 48-56
    CrossrefPubMedGoogle Scholar
  • 55 Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22 (01) 54-61
    CrossrefPubMedGoogle Scholar
  • 56 Johnson KW, Morin SM, Wroblewski VJ, Johnson MP. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats. Cephalalgia 2019; 39 (10) 1241-1248
    CrossrefPubMedGoogle Scholar
  • 57 Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019; 394 (10210): 1765-1774
    CrossrefPubMedGoogle Scholar
  • 58 Ailani J, Burch RC, Robbins MS. Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 2021; 61 (07) 1021-1039
    CrossrefPubMedGoogle Scholar
  • 59 Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 2020; 40 (13) 1511-1522
    CrossrefPubMedGoogle Scholar
  • 60 Stauffer VL, Turner I, Kemmer P. et al. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials. J Headache Pain 2020; 21 (01) 79
    CrossrefPubMedGoogle Scholar
  • 61 Smith TR, Spierings ELH, Cady R. et al. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. [published correction appears in J Headache Pain. 2021 May 25;22(1):46] J Headache Pain 2021; 22 (01) 16
    CrossrefPubMedGoogle Scholar
  • 62 Nahas SJ, Naegel S, Cohen JM. et al. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 2021; 22 (01) 141
    CrossrefPubMedGoogle Scholar
  • 63 Aimovig (erenumab-aooe) Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2020
    Google Scholar
  • 64 Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: a new safety risk for patients treated with erenumab. Headache 2021; 61 (01) 202-208
    CrossrefPubMedGoogle Scholar
  • 65 Dodick DW, Tepper SJ, Ailani J. et al. Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache 2021; 61 (09) 1411-1420
    CrossrefPubMedGoogle Scholar
  • 66 Cohen-Barak O, Weiss S, Rasamoelisolo M. et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia 2018; 38 (13) 1960-1971
    CrossrefPubMedGoogle Scholar
  • 67 AJOVY (fremanezumab-vfrm) Injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc; 2018
    Google Scholar
  • 68 Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; 2018
    Google Scholar
  • 69 Baker B, Schaeffler B, Beliveau M. et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect 2020; 8 (02) e00567
    CrossrefPubMedGoogle Scholar
  • 70 Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache 2020; 60 (10) 2220-2231
    CrossrefPubMedGoogle Scholar
  • 71 VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc; 2020
    Google Scholar
  • 72 Blumenfeld AM, Frishberg BM, Schim JD. et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review. Pain Ther 2021; 10 (02) 809-826
    CrossrefPubMedGoogle Scholar
  • 73 Croop R, Lipton RB, Kudrow D. et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397 (10268): 51-60
    CrossrefPubMedGoogle Scholar
  • 74 Ailani J, Lipton RB, Goadsby PJ. et al; ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med 2021; 385 (08) 695-706
    CrossrefPubMedGoogle Scholar
  • 75 NURTEC ODT. Package insert. Biohaven Pharmaceuticals Inc; May 2021
    Google Scholar
  • 76 QULIPTA (atogepant). Package insert. Allergan USA, Inc; 2021
    PubMedGoogle Scholar
  • 77 Halker Singh RB, Ailani J, Robbins MS. Neuromodulation for the acute and preventive therapy of migraine and cluster headache. Headache 2019; 59 (Suppl. 02) 33-49
    CrossrefPubMedGoogle Scholar
  • 78 Relivion® Wearable Brain Neuromodulation Technology Cleared by FDA for the Treatment of Migraine. www.businesswire.com. Published March 2, 2021. Accessed January 17, 2022 at: https://www.businesswire.com/news/home/20210302005356/en/Relivion%C2%AE-Wearable-Brain-Neuromodulation-Technology-Cleared-by-FDA-for-the-Treatment-of-Migraine
    PubMedGoogle Scholar
  • 79 Starling AJ, Tepper SJ, Marmura MJ. et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38 (06) 1038-1048
    CrossrefPubMedGoogle Scholar
  • 80 Irwin SL, Qubty W, Allen IE, Patniyot I, Goadsby PJ, Gelfand AA. Transcranial magnetic stimulation for migraine prevention in adolescents: a pilot open-label study. Headache 2018; 58 (05) 724-731
    CrossrefPubMedGoogle Scholar
  • 81 electroCore. electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study. GlobeNewswire News Room. Published December 8, 2020. Accessed January 17, 2022 at: https://www.globenewswire.com/news-release/2020/12/08/2141280/0/en/electroCore-Announces-Positive-Top-Line-Results-from-PREMIUM-II-Migraine-Prevention-Study.html
    PubMedGoogle Scholar
  • 82 Tassorelli C, Grazzi L, de Tommaso M. et al; PRESTO Study Group. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 2018; 91 (04) e364-e373
    CrossrefPubMedGoogle Scholar
  • 83 Schoenen J, Vandersmissen B, Jeangette S. et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013; 80 (08) 697-704
    CrossrefPubMedGoogle Scholar
  • 84 von Luckner A, Riederer F. Magnesium in migraine prophylaxis - Is there an evidence-based rationale? A systematic review. Headache 2018; 58 (02) 199-209
    CrossrefPubMedGoogle Scholar
  • 85 Grazzi L, Toppo C, D'Amico D. et al. Non-pharmacological approaches to headaches: non-invasive neuromodulation, nutraceuticals, and behavioral approaches. Int J Environ Res Public Health 2021; 18 (04) 1503
    CrossrefPubMedGoogle Scholar
  • 86 Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacogn Rev 2011; 5 (09) 103-110
    CrossrefPubMedGoogle Scholar
  • 87 Tepper SJ. Nutraceutical and other modalities for the treatment of headache. Continuum (Minneap Minn) 2015; 21 (4 Headache): 1018-1031
    PubMedGoogle Scholar
  • 88 Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: a systematic review. Medicine (Baltimore) 2019; 98 (03) e14099
    CrossrefPubMedGoogle Scholar
  • 89 Kvisvik EV, Stovner LJ, Helde G, Bovim G, Linde M. Headache and migraine during pregnancy and puerperium: the MIGRA-study. J Headache Pain 2011; 12 (04) 443-451
    CrossrefPubMedGoogle Scholar
  • 90 Saldanha IJ, Cao W, Bhuma MR. et al. Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review. Headache 2021; 61 (01) 11-43
    CrossrefPubMedGoogle Scholar
  • 91 Riggins N, Ehrlich A. The use of behavioral modalities for headache during pregnancy and breastfeeding. Curr Pain Headache Rep 2021; 25 (10) 66
    CrossrefPubMedGoogle Scholar
  • 92 Burch R. Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review. Headache 2020; 60 (01) 200-216
    CrossrefPubMedGoogle Scholar
  • 93 Hale TW. Hale's Medications and Mothers' Milk. 2021. New York, NY: Springer Publishing Company; ; 2020
    Google Scholar
  • 94 Wong HT, Khalil M, Ahmed F. OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. J Headache Pain 2020; 21 (01) 129
    CrossrefPubMedGoogle Scholar
  • 95 Bhola R, Kinsella E, Giffin N. et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain 2015; 16: 535
    CrossrefPubMedGoogle Scholar
  • 96 Campbell JK, Penzien DB, Wall EM. US Headache Consortium, American Academy of Family Physicians, American Academy of Neurology, American Headache Society, American College of Emergency Physicians, American College of Physicians-American Society of Internal Medicine, American Osteopathic Association, National Headache Foundation. Evidence-based guidelines for migraine headache: behavioral and physical treatments. Accessed October 25, 2022 at: http://tools.aan.com/professionals/practice/pdfs/gl0089.pdf
    PubMedGoogle Scholar
  • 97 Singer AB, Buse DC, Seng EK. Behavioral treatments for migraine management: useful at each step of migraine care. Curr Neurol Neurosci Rep 2015; 15 (04) 14
    CrossrefPubMedGoogle Scholar
  • 98 Linde K, Allais G, Brinkhaus B. et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016; (06) CD001218
    PubMedGoogle Scholar
  • 99 Zhang N, Houle T, Hindiyeh N, Aurora SK. Systematic review: acupuncture vs standard pharmacological therapy for migraine prevention. Headache 2020; 60 (02) 309-317
    CrossrefPubMedGoogle Scholar
  • 100 John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache 2007; 47 (05) 654-661
    CrossrefPubMedGoogle Scholar
  • 101 Pistoia F, Sacco S, Carolei A. Behavioral therapy for chronic migraine. Curr Pain Headache Rep 2013; 17 (01) 304
    CrossrefPubMedGoogle Scholar